Short Ragweed Injection
NDC Package 49643-315-50

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Short Ragweed (ambrosia artemisiifolia) injection is studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21. This formulation utilizes a injection delivery system. Marketed by Allermed Laboratories, Inc., this product is identified by NDC 49643-315 and is authorized under FDA application BLA103113.

Identification & Billing

NDC Package Code
49643-315-50
Package Description
50 mL in 1 VIAL, MULTI-DOSE
Product Code
49643-315
11-Digit Billing Format
49643031550
RxNorm Crosswalk
  • RxCUI: 896140 - short ragweed pollen extract 100 MG/ML Injectable Solution
  • RxCUI: 896140 - Ambrosia artemisiifolia pollen extract 1 GM per 10 ML Injectable Solution
  • RxCUI: 896140 - Ambrosia artemisiifolia pollen extract 100 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Short Ragweed
Non-Proprietary Name
Ambrosia Artemisiifolia
Substance Name
Ambrosia Artemisiifolia Pollen
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
  • Cutaneous - Administration to the skin.
  • Intradermal - Administration within the dermis.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
AMBROSIA ARTEMISIIFOLIA POLLEN 1 g/10mL
Pharmacologic Class
Usage Information
Studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21. Immunotherapy with the appropriate dosage of short ragweed pollen extract is effective in reducing symptoms of hay fever and asthma resulting from exposure to short ragweed pollen (9, 10, 11), and it is believed to be effective with extract of giant ragweed, although carefully controlled studies are unavailable. However, clinical observations and known cross reactivity between short and giant ragweed pollens have led to the practice of using a mixture of the two species for skin testing and treatment 22, 23, 24, 25, 26, 27. This form of treatment is recommended for patients who cannot avoid exposure to pollen and who do not obtain satisfactory relief of symptoms from other medications, such as antihistamines. Immunologic changes resulting from treatment with short ragweed pollen extract are believed to include: The induction of specific anti-ragweed IgG antibodies commonly referred to as "blocking antibodies" 12, 13. A decrease in the elevation of ragweed specific IgE during and immediately following the ragweed pollen season 14. A reduction of circulating anti-ragweed IgE after long-term immunotherapy 15. A decrease in skin reactivity to the extract 16 and a decrease in leukocyte sensitivity to histamine release 17 after long-term immunotherapy.

Regulatory & Marketing

Labeler Name
Allermed Laboratories, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA103113
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-22-1982
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (49643-315). Click a package code to view its specific billing and regulatory data.

49643-315-05
5 mL in 1 VIAL, MULTI-DOSE
49643-315-10
10 mL in 1 VIAL, MULTI-DOSE
49643-315-30
30 mL in 1 VIAL, MULTI-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49643-315-50 identifies a specific commercial package of 50 ml in 1 vial, multi-dose of Short Ragweed, a human prescription drug labeled by Allermed Laboratories, Inc.. This injection is formulated for cutaneous; intradermal; subcutaneous use and contains ambrosia artemisiifolia pollen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allermed Laboratories, Inc. on March 22, 1982. The current certification is valid through December 31, 2026.

How is this Allermed Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49643031550. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49643-315-50
11-Digit CMS (5-4-2)
49643-0315-50

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.